{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134840","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.399021+00:00","generated_at":"2026-06-02T05:23:17.255281+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fate Therapeutics treats first SLE patient with FT819; advances autoimmune pipeline","bullets":["First SLE patient dosed in Phase 1 autoimmunity study of FT819 (CD19 CAR T); discharged after 3 days with no notable AEs.","FT819 translational data: rapid deep B-cell depletion, tissue trafficking, plasma cell depletion; fludarabine not required in some cases.","FT522 (CAR NK) initial observations: rapid sustained B-cell depletion and enhanced persistence vs FT596 in first two BCL patients.","Company completed dose escalation in FT819 BCM study; will focus FT819 solely on autoimmunity; FT522 IND for autoimmune diseases expected mid-2024.","FT819 safety in BCM study: no DLTs, ICANS, or GvHD; low-grade CRS in 14% of patients; no study discontinuations or deaths."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134840","json":"https://secwatch.observer/filing/0001193125-24-134840.json","markdown":"https://secwatch.observer/filing/0001193125-24-134840.md","text":"https://secwatch.observer/filing/0001193125-24-134840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524134840/0001193125-24-134840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000119312524134840/d675282d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:23:17.255281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}